local
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
By By Castle Biosciences, Inc. at Denton Record-Chronicle
· July 14, 2026
· 1 min read
Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis
Why this matters in Denton News
The New York State Department of Health's approval of Castle Biosciences' AdvanceAD-Tx test has implications for Denton residents who suffer from moderate-to-severe atopic dermatitis. As a community within the Dallas-Fort Worth area, Denton's access to cutting-edge medical treatments is crucial for its growing population. The approval of this precision medicine test could lead to increased availability of targeted treatment options for local patients. This development may also attract medical professionals and researchers to the area, potentially boosting the local economy and enhancing Denton's reputation as a hub for innovative healthcare solutions. Furthermore, the expansion of Castle Biosciences' test may prompt local healthcare providers to reevaluate their treatment protocols for atopic dermatitis, ultimately improving patient outcomes in Denton and surrounding communities.
About this story
Original reporting by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: July 14, 2026 ·
Source: Denton Record-Chronicle ·
Reading time: 1 min
Get more Denton News stories like this
Free weekly briefing covering local and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis
When was this published? This article was first published on July 14, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By Castle Biosciences, Inc. at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter